ABBVIE INC. (ABBV)
Loading chart
Key facts
- Open
- Previous close
- Day range
- 52-week range
- Volume
- Short % of shares
- Days to cover
- Market cap
- 514.92B
- Exchange
- XNYS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
- Industry
- PHARMACEUTICAL PREPARATIONS
- Employees
- 57,000
- Listed
- 2012-12-10
- Website
- www.abbvie.com